BioLife Solutions (NASDAQ:BLFS) Research Coverage Started at Stephens

Stephens began coverage on shares of BioLife Solutions (NASDAQ:BLFS) in a research report released on Tuesday, January 7th, Briefing.com Automated Import reports. The firm issued an overweight rating and a $23.00 target price on the medical equipment provider’s stock.

BLFS has been the subject of a number of other research reports. BidaskClub cut BioLife Solutions from a buy rating to a hold rating in a research note on Wednesday, December 11th. TheStreet upgraded BioLife Solutions from a c rating to a b- rating in a research note on Friday, November 29th. Oppenheimer assumed coverage on BioLife Solutions in a research note on Wednesday, November 20th. They issued an outperform rating and a $22.00 target price for the company. HC Wainwright restated a buy rating and issued a $26.00 target price (up previously from $23.00) on shares of BioLife Solutions in a research note on Monday, December 16th. Finally, Maxim Group set a $26.00 target price on BioLife Solutions and gave the company a buy rating in a research note on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $22.50.

Shares of BLFS stock opened at $15.90 on Tuesday. The stock has a market capitalization of $323.76 million, a PE ratio of 113.57, a P/E/G ratio of 11.51 and a beta of 1.24. BioLife Solutions has a 1-year low of $11.60 and a 1-year high of $22.44. The business has a 50-day moving average of $16.13 and a 200 day moving average of $17.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 5.33.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. BioLife Solutions had a return on equity of 5.37% and a net margin of 46.77%. The business had revenue of $6.60 million during the quarter, compared to analysts’ expectations of $7.65 million. Analysts anticipate that BioLife Solutions will post 0.05 EPS for the current year.

In other BioLife Solutions news, CRO James Mathers sold 2,500 shares of BioLife Solutions stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $16.05, for a total value of $40,125.00. Following the completion of the sale, the executive now owns 19,884 shares of the company’s stock, valued at approximately $319,138.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Greef Roderick De sold 10,000 shares of BioLife Solutions stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $15.46, for a total value of $154,600.00. Following the completion of the sale, the chief financial officer now directly owns 35,859 shares of the company’s stock, valued at approximately $554,380.14. The disclosure for this sale can be found here. In the last three months, insiders sold 102,247 shares of company stock valued at $1,625,347. Corporate insiders own 27.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Roubaix Capital LLC grew its holdings in shares of BioLife Solutions by 73.5% in the fourth quarter. Roubaix Capital LLC now owns 138,308 shares of the medical equipment provider’s stock worth $2,238,000 after acquiring an additional 58,584 shares during the period. Granahan Investment Management Inc. MA lifted its position in BioLife Solutions by 113.5% during the third quarter. Granahan Investment Management Inc. MA now owns 270,085 shares of the medical equipment provider’s stock valued at $4,490,000 after purchasing an additional 143,595 shares in the last quarter. State Street Corp lifted its position in BioLife Solutions by 15.9% during the third quarter. State Street Corp now owns 130,210 shares of the medical equipment provider’s stock valued at $2,165,000 after purchasing an additional 17,861 shares in the last quarter. Alpine Woods Capital Investors LLC lifted its position in BioLife Solutions by 9.0% during the third quarter. Alpine Woods Capital Investors LLC now owns 10,900 shares of the medical equipment provider’s stock valued at $181,000 after purchasing an additional 900 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in BioLife Solutions by 94.8% during the third quarter. Russell Investments Group Ltd. now owns 582,843 shares of the medical equipment provider’s stock valued at $9,685,000 after purchasing an additional 283,603 shares in the last quarter. 50.16% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: S&P/ASX 200 Index

Analyst Recommendations for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News